Showing results (2921-2930 of 6,794) with videos related to
Sort By:
Pageof 680
Clinical Therapeutics|August 12, 2014
Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysisElias Zintzaras, Michael Miligkos, Panayiotis Ziakas, et al.Clinical Therapeutics|August 6, 2014
Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical studyJong-Chan Youn, Sang-Hyun Ihm, Jang-Ho Bae, et al.Clinical Therapeutics|August 7, 2014
Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and womenMi Jo Kim, Hyeong-Seok Lim, Seokjoon Jin, et al.Clinical Therapeutics|December 3, 2013
Hydromorphone: evolving to meet the challenges of today's health care environmentThomas B GregoryClinical Therapeutics|December 31, 2011
Pharmacokinetics of vandetanib: three phase I studies in healthy subjectsPaul Martin, Stuart Oliver, Sarah-Jane Kennedy, et al.Clinical Therapeutics|December 1, 2012
Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patientsGrace C Lee, Hansheng Liou, Russell Yee, et al.Clinical Therapeutics|December 4, 2012
A randomized, double-blind, placebo-controlled study of acetaminophen 1000 mg versus acetaminophen 650 mg for the treatment of postsurgical dental painDaniel S Qi, Lisa G May, Brenda Zimmerman, et al.Clinical Therapeutics|January 1, 1990
Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administrationH Kumagae, Y Koiwaya, K TanakaClinical Therapeutics|January 1, 2013
Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trialSang-Hyun Kim, Myung-Ki Seo, Myeong-Ho Yoon, et al.Clinical Therapeutics|August 14, 2013
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extensionLuigi Giorgi, Afsaneh Asgharian, Brian HunterPageof 680